{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:55:58Z","timestamp":1794243358717,"version":"4.9.0"},"reference-count":35,"publisher":"FapUNIFESP (SciELO)","issue":"suppl 2","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cad. Sa\u00fade P\u00fablica"],"abstract":"<jats:p>As doen\u00e7as tropicais negligenciadas constituem um grupo heterog\u00eaneo de enfermidades que apresentam como caracter\u00edstica comum afetarem popula\u00e7\u00f5es pobres e desassistidas, com pouca capacidade de vocaliza\u00e7\u00e3o e de poder pol\u00edtico. Em consequ\u00eancia, recebem pouca aten\u00e7\u00e3o da ind\u00fastria farmac\u00eautica e da academia. O presente estudo teve como prop\u00f3sito resumir o estado da arte quanto ao desenvolvimento de vacinas para tr\u00eas doen\u00e7as tropicais negligenciadas de relev\u00e2ncia no Brasil, a doen\u00e7a de Chagas, a esquistossomose mansoni e as leishmanioses. Para tanto, realizou-se uma revis\u00e3o narrativa da literatura cient\u00edfica, na qual foram inclu\u00eddas publica\u00e7\u00f5es que permitiram tra\u00e7ar um panorama atual do desenvolvimento de vacinas para as tr\u00eas doen\u00e7as. Essas vacinas est\u00e3o em est\u00e1gios distintos de desenvolvimento. Os projetos de desenvolvimento de vacinas contra a tripanossom\u00edase americana ainda n\u00e3o chegaram \u00e0 fase cl\u00ednica de avalia\u00e7\u00e3o. J\u00e1 para a esquistossomose h\u00e1 candidatos \u00e0 vacina em fase avan\u00e7ada de avalia\u00e7\u00e3o cl\u00ednica. Para as leishmanioses j\u00e1 existem vacinas veterin\u00e1rias licenciadas e produtos candidatos \u00e0 vacina humana em etapa intermedi\u00e1ria de avalia\u00e7\u00e3o cl\u00ednica. O reduzido financiamento para esses projetos tem contribu\u00eddo para retardar o desenvolvimento dos produtos.<\/jats:p>","DOI":"10.1590\/0102-311x00215720","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T22:58:06Z","timestamp":1605913086000},"source":"Crossref","is-referenced-by-count":18,"title":["O desenvolvimento de vacinas contra as doen\u00e7as tropicais negligenciadas"],"prefix":"10.1590","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1145-9672","authenticated-orcid":false,"given":"Expedito Jos\u00e9 de Albuquerque","family":"Luna","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1048-8332","authenticated-orcid":false,"given":"S\u00e9rgio Roberto de Souza Le\u00e3o da Costa","family":"Campos","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2020]]},"reference":[{"key":"ref1","series-title":"Working to overcome the global impact of neglected tropical diseases - 1st WHO Report on Neglected Tropical Diseases","year":"2010"},{"key":"ref2","series-title":"Integrating neglected tropical diseases into global health and development - 4th WHO Report on Neglected Tropical Diseases","year":"2017"},{"key":"ref3","series-title":"Sa\u00fade de A a Z."},{"key":"ref4","series-title":"Schistosomiasis."},{"key":"ref5","series-title":"Guia de Vigil\u00e2ncia em Sa\u00fade","year":"2019"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1017\/S0031182017002268","article-title":"Systematic review and meta-analysis on schistosomiasis mansoni infection prevalence, and associated risk factors in Brazil","volume":"145","author":"Casavechia MTG","year":"2018","journal-title":"Parasitology"},{"key":"ref7","series-title":"Inqu\u00e9rito nacional de preval\u00eancia da esquistossomose mansoni e geo-helmintoses","author":"Katz N","year":"2018"},{"key":"ref8","series-title":"Chagas disease."},{"key":"ref9","series-title":"Boletim Epidemiol\u00f3gico: doen\u00e7a de Chagas."},{"key":"ref10","first-page":"7","article-title":"II Consenso Brasileiro em Doen\u00e7a de Chagas.","volume":"25","author":"Dias JCP","year":"2016","journal-title":"Epidemiol Serv Sa\u00fade"},{"key":"ref11","series-title":"Leishmaniasis."},{"key":"ref12","series-title":"Casos confirmados de leishmaniose visceral, Brasil, 1990 a 2018."},{"key":"ref13","series-title":"Casos de leishmaniose tegumentar, Brasil, 1990 a 2018."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1186\/s13071-016-1799-4","article-title":"Schistosomiasis vaccines where do we stand?","volume":"9","author":"Tebeje BM","year":"2016","journal-title":"Parasit Vectors"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00281-020-00789-x","article-title":"Schistosomiasis from immunopathology to vaccines","volume":"42","author":"McManus DP","year":"2020","journal-title":"Semin Immunopathol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/14760584.2016.1131127","article-title":"Development of a schistosomiasis vaccine","volume":"15","author":"Molehin AJ","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1016\/j.vaccine.2016.03.079","article-title":"Advancing a vaccine to prevent human schistosomiasis","volume":"34","author":"Merrifield M","year":"2016","journal-title":"Vaccine"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.pt.2016.10.010","article-title":"Sm-p80-based schistosomiasis vaccine preparation for human clinical trials","volume":"33","author":"Siddiqui AA","year":"2017","journal-title":"Trends Parasitol"},{"key":"ref19","first-page":"347","article-title":"Development of paramyosin as a vaccine candidate for schistosomiasis","volume":"6","author":"Jiz MA","year":"2015","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"105168","DOI":"10.1016\/j.actatropica.2019.105168","article-title":"Immunity and vaccine development efforts against Trypanosoma cruzi","volume":"200","author":"Rios LE","year":"2019","journal-title":"Acta Trop"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"489758","DOI":"10.1155\/2015\/489758","article-title":"Experimental vaccines against Chagas disease a journey through history","volume":"2015","author":"Rodr\u00edguez-Morales O","year":"2015","journal-title":"J Immunol Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"165591","DOI":"10.1016\/j.bbadis.2019.165591","article-title":"Epidemiology and pathogenesis of maternal-fetal transmission of Trypanosoma cruzi and a case for vaccine development against congenital Chagas disease","volume":"1866","author":"Rios L","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13071-015-0738-0","article-title":"Prophylactic and therapeutic DNA vaccines against Chagas disease","volume":"8","author":"Arce-Fonseca M","year":"2015","journal-title":"Parasit Vectors"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"165658","DOI":"10.1016\/j.bbadis.2019.165658","article-title":"Chagas disease vaccine design the search for an efficient Trypanosoma cruzi immune-mediated control","volume":"1866","author":"Bivona AE","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/ijpvm.IJPVM_116_18","article-title":"Leishmania vaccines entered in clinical trials a review of literature","volume":"10","author":"Moafi M","year":"2019","journal-title":"Int J Prev Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2015.03.017","article-title":"Vaccines for visceral leishmaniasis a review","volume":"422","author":"Jain K","year":"2015","journal-title":"J Immunol Methods"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"569193","DOI":"10.1155\/2014\/569193","article-title":"Vaccines for canine leishmaniasis","volume":"2014","author":"Foroughi-Parvar F","year":"2014","journal-title":"Adv Prev Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.vaccine.2014.11.039","article-title":"Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum","volume":"33","author":"Fiuza JA","year":"2015","journal-title":"Vaccine"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/tmi.13382","article-title":"Commercially approved vaccines for canine leishmaniosis a review of available data on their safety and ef?cacy","volume":"25","author":"Velez R","year":"2020","journal-title":"Trop Med Int Health"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13071-016-1553-y","article-title":"Possibilities and challenges for developing a successful vaccine for leishmaniasis","volume":"9","author":"Srivastav S","year":"2016","journal-title":"Parasit Vectors"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/pim.12315","article-title":"DNA vaccine against visceral leishmaniasis a promising approach for prevention and control","volume":"38","author":"Kumar A","year":"2016","journal-title":"Parasite Immunol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fimmu.2020.00204","article-title":"The delay in the licensing of protozoal vaccines a comparative history","volume":"11","author":"Palatnik-de-Sousa CB","year":"2020","journal-title":"Front Immunol"},{"key":"ref33","series-title":"A study of the efficacy and safety of the LEISH-F2+MPL-SE vaccine for treatment of cutaneous leishmaniasis.","author":"Piazza F"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1016\/j.vaccine.2015.12.071","article-title":"Status of vaccine research and development of vaccines for leishmaniasis","volume":"34","author":"Gillespie PM","year":"2016","journal-title":"Vaccine"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","article-title":"RTS,S\/AS01 vaccine (MosquirixTM) an overview","volume":"16","author":"Laurens MB","year":"2020","journal-title":"Hum Vaccin Immunother"}],"container-title":["Cadernos de Sa\u00fade P\u00fablica"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/csp\/v36s2\/1678-4464-csp-36-s2-e00215720.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T04:37:13Z","timestamp":1611463033000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0102-311X2020001402005&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":35,"journal-issue":{"issue":"suppl 2","published-online":{"date-parts":[[2020]]}},"alternative-id":["S0102-311X2020001402005"],"URL":"https:\/\/doi.org\/10.1590\/0102-311x00215720","relation":{},"ISSN":["1678-4464","0102-311X"],"issn-type":[{"value":"1678-4464","type":"electronic"},{"value":"0102-311X","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"article-number":"e00215720"}}